Anti-apoptotic Bcl-2 proteins are over-expressed in a number of cancers, including leukemias, and are frequently associated with resistance to conventional chemotherapeutic drugs. ABT-737, a BH-3 mimetic, inhibits the pro-survival function of Bcl-2, Bcl-X L , and Bcl-w. We show that ABT-737 was effective as a single agent against a panel of pediatric acute lymphoblastic leukemia ( 
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Introduction
The introduction of combination chemotherapy regimens for childhood ALL, along with advances in supportive care, have dramatically improved survival in this disease to a rate now approaching 80% in developed countries (Pui and Evans, 2006) . Despite this success, the overall survival of the 15-20% of patients who relapse is poor, with most patients succumbing to their disease (Bailey et al., 2008) . Relapse is frequently associated with acquired resistance to central components of induction therapy protocols, including glucocorticoids and L-asparaginase (L-asp) (Bailey et al., 2008) .
The majority of conventional cytotoxic agents indirectly induce apoptosis through DNA damage and cell cycle arrest. However, malignant cells frequently acquire defects, including oncogene activation and deregulation of apoptotic signaling pathways, thereby allowing them to evade apoptosis (Hanahan and Weinberg, 2000) . For these reasons, and the high levels of toxicity frequently observed with traditional treatment, recent approaches to cancer therapy have focused on targeting key components of pathways shown to be fundamental to tumor survival and disease progression . This approach is aimed to circumvent acquired drug resistance pathways and re-sensitize the malignant cell to apoptosis.
The Bcl-2 family of proteins are central regulators of apoptosis, and cell survival is determined by the interaction and balance between pro-apoptotic and anti-apoptotic family members (Adams and Cory, 1998) . The Bcl-2 family consists of at least 20 proteins, each of which share at least one of the four conserved Bcl-2 homology (BH) domains, and is divided into three subclasses. Multidomain pro-apoptotic proteins Bax and Bak are essential for apoptosis and they oligomerize at the mitochondria to disrupt the outer mitochondrial membrane and facilitate the release of pro-apoptotic proteins including cytochrome c (Adams and Cory, 1998) . Anti-apoptotic family members (Bcl-2, Bcl-X L , Bcl-w, Mcl-1, and A1) maintain outer mitochondrial membrane integrity by suppressing the function of Bax and Bak (Zhou et al., 1997) . Another subclass of the Bcl-2 family (including Bim, Bid, Bad, Hrk, Bik, Bmf, Puma, and Noxa) are referred to as "BH3-This article has not been copyedited and formatted. The final version may differ from this version. only" proteins and only share the BH3 domain with other family members (Huang and Strasser, 2000) . There are two proposed mechanisms by which BH3-only proteins function. The "indirect" model proposes that the BH3 family of proteins unleash Bax and Bak from being suppressed by pro-survival Bcl-2 family proteins (Willis et al., 2007) . Alternatively, the "direct" action model suggests that Bid and Bim can also interact with pro-apoptotic Bax and Bak, inducing their oligomerization, and subsequent apoptosis (Letai et al., 2002 ).
An imbalance of pro-and anti-apoptotic Bcl-2 family proteins is a common feature of malignancy, including ALL, and can render tumor cells refractory to chemotherapy (Campana et al., 1993) . The ability of pro-survival members of the Bcl-2 family to facilitate evasion of cell death signals has made them attractive targets for cancer drug discovery (Zhang et al., 2007) . A number of small-molecule inhibitors of pro-survival Bcl-2 family members are at various stages of preclinical and clinical development (Becattini et al., 2004; Oltersdorf et al., 2005) . ABT-737, and its closely related orally available homolog ABT-263, have shown potent single agent in vitro and in vivo activity against cancer cell lines and primary cells, including ALL (Del Gaizo Moore et al., 2008; Lock et al., 2008; Oltersdorf et al., 2005) . Moreover, both compounds significantly potentiate the efficacy of established and novel chemotherapeutic drugs, indicating a high priority for clinical trials using novel drug combinations (Kang et al., 2007; Kuroda et al., 2008) . ABT-737 exhibits low affinity binding to the anti-apoptotic Mcl-1 and A1 proteins, and resistance to ABT-737 in cancer cells lines has been attributed to high levels of Mcl-1 and A1 expression (Deng et al., 2007; Lin et al., 2007) . Nevertheless, the determinants of in vivo sensitivity to ABT-737/263 remain poorly understood.
In this study we examined the in vitro ABT-737 sensitivity of a panel of leukemia cell lines, and the in vivo and ex vivo sensitivity of a panel of B-cell precursor ALL (BCP-ALL) xenografts established in non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice directly from patient explants (Liem et al., 2004) , in relation to Bcl-2 family protein expression. While Mcl-1 expression significantly correlated with ABT-737 sensitivity in leukemia cell lines, Bim protein This article has not been copyedited and formatted. The final version may differ from this version. and Microbial Biosciences, University of Sydney), respectively. CEM, Nalm-6, Molt-4, K562 and HL-60 cells used in the study were laboratory stock cell lines. Cell lines were maintained in static suspension culture in RPMI-1640 media supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 µg/mL), and L-glutamine (2 mM).
Procedures by which we previously established continuous xenografts from childhood ALL biopsies in immune deficient NOD/SCID (NOD/LtSz-scid/scid) mice are described in detail elsewhere (Liem et al., 2004) . Xenograft characteristics are presented in Table 1 . For all ex vivo experiments, xenograft cells were retrieved from cryostorage and resuspended in QBSF-60 medium (Quality Biological, Gaithersburg, MD) supplemented with Flt-3 ligand (20 ng/mL; kindly provided by Amgen, Thousand Oaks, CA), penicillin (100 U/mL), streptomycin (100 µg/mL), and Lglutamine (2 mM). Viability was determined by exclusion of 0.2% trypan blue. For cytotoxicity experiments, cells were equilibrated in medium in a humidified atmosphere overnight at 37°C, 5% CO 2 prior to drug treatment. An equivalent volume of an appropriate vehicle control was added to control cells. Cells were harvested by centrifugation at 490 x g for 10 min and washed twice with PBS.
In some experiments xenograft cells were co-cultured on a confluent layer of murine MS-5 stromal cells overnight then treated with 10 -12 to 10 -6 M ABT-737 for up to 48 h. Prior to harvesting 20,000 10 µm latex beads (Beckman Coulter, Harbor Boulevard, CA) were added to each well. and quantified with reference to the bead control, as described previously (Liem et al., 2004) .
In vitro cytotoxicity assays using primary murine lymphoid cells. Femurs and tibias were harvested from multiple wild-type, Bim -/-, and Puma -/-C57BL/6 mice. Generation of the knockout mice has been described previously (Michalak et al., 2009) plate with concentrations of ABT-737 ranging from 10 -9 to 10 -6 M, in a humidified atmosphere with 10% CO 2 at 37°C for 24 hours. Cell viability was quantified using PI staining as described above.
MTT colorimetric assay.
Procedures by which leukemia cell lines and xenograft cells were assessed for ABT-737 sensitivity by MTT assay have been described in detail previously (Bachmann et al., 2007 In vivo efficacy of ABT-737 against pediatric ALL xenografts. Procedures by which we established xenografts from pediatric ALL biopsy specimens in NOD/SCID mice and assessed their in vivo drug sensitivity have been described in detail elsewhere (Liem et al., 2004 (Kaplan, 1958) and survival curves were compared by logrank test. For comparisons between xenografts and drug treatments, the median EFS for control mice was subtracted from the median EFS for drug-treated mice to generate a leukemia growth delay (LGD). Mice were also monitored closely for signs of drug-related toxicity (weight loss, lethargy, ruffled fur, etc.) and euthanized at the first indication of morbidity. Mice were excluded from the group if they developed spontaneous murine thymic lymphomas. All experimental studies had prior approval from the Animal Care and Ethics Committee of the University of New South Wales.
This article has not been copyedited and formatted. The final version may differ from this version. Figure 1A and Table 1 ). To validate the results obtained using the MTT cytotoxicity assay, the viability of two cell lines (Nalm-6 and Jurkat) exposed to increasing concentrations of ABT-737 was assessed using the trypan blue exclusion assay. The results were comparable to those reported in Table 1 , with IC50 values of >10 µM and 3.6 µM for Nalm-6 and Jurkat cell lines, respectively (data not shown). There was no apparent lineage-specific relationship with ABT-737 sensitivity, with a range of IC50 values observed over the cell lines tested. In contrast to the cell lines, all 9 ALL xenografts were acutely sensitive to ABT-737 ex vivo ( Figure   1A ), with IC50 values ranging from 1 to 45 nM (Table 1 ). The median IC50 of the xenograft panel (3.7 nM) was 810-fold less than that of the panel of cell lines (3.0 µM; Table 1) .
ABT-737 has demonstrated single agent in vivo activity against various human solid tumor xenograft models and murine malignancies (Oltersdorf et al., 2005; Trudel et al., 2007) . We therefore next assessed the in vivo efficacy of ABT-737 against a panel of 8 human BCP-ALL xenografts, which were derived from patients who exhibited diverse clinical outcomes, and manifest as a systemic disease in NOD/SCID mice. At a dose of 25 mg/kg (approximately 25% of the maximum-tolerated dose; MTD) ABT-737 significantly delayed the progression of 5/8 xenografts (ALL-3, -7, -10, -11 and -17) by 7-27 days compared with control animals (Figure 1B-C and Table   1 ). At a higher dose (60 mg/kg) ABT-737 delayed the progression of all xenografts by 12-31 days (Table 1) . The median and ranges of EFS values of treated and control mice for all xenografts are shown in Supplementary Table 1 . The response to ABT-737 was dose-dependent ( Figure 1D ), albeit marginally for ALL-3, -7 and -17.
This article has not been copyedited and formatted. The final version may differ from this version. Since we have shown above that ALL xenograft cells are sensitive to ABT-737 both ex vivo
and in vivo, we tested whether ex vivo culture conditions that mimic the bone marrow microenvironment (low oxygen or stromal co-culture) affected sensitivity to ABT-737. These conditions have previously been shown to alter sensitivity of leukemia cells to chemotherapeutic drugs (Yang et al., 2006) . While low oxygen decreased the sensitivity of Molt-4 cells to 4-HPR, it had no effect on the sensitivity of ALL-3 or ALL-18 to ABT-737 (Figure 2A) . Furthermore, the sensitivity of ALL-3 to DEX was substantially decreased by stromal co-culture, although stromal co-culture had no effect on the sensitivity of ALL-3 and ALL-18 to ABT-737 ( Figure 2B ). These results may explain in part why the exquisite ex vivo sensitivity of these cells is also reflected in vivo. with those from wild-type Puma -/-mice ( Figure 3C ) and xenografts.
In an effort to understand the diversity in ABT-737 responses between leukemia cell lines and xenograft cells, we directly compared protein expression levels of Bcl-2 family members, which were all normalized to a common control cell lysate that was included in each gel. While leukemia cell lines expressed significantly higher levels of Bcl-w and Bcl-X L , and higher levels of
Mcl-1 that approached significance, xenograft cells expressed higher levels of Bcl-2 ( Figure 3D , top row). Moreover, the three cell lines that were most sensitive to CEM, expressed levels of Mcl-1 that were comparable to those in xenograft cells ( Figure 3D ). In terms of pro-apoptotic proteins, the cell lines expressed significantly higher levels of Puma, Bim and Bak, but lower levels of Bax, than xenograft cells ( Figure 3D , bottom row). With the exception of Bcl-2, relative expression levels of Bcl-2 family members were less variable across the panel of 9 xenografts compared with the 8 leukemia cell lines.
Overall, these results indicate a role for Bim in the in vitro and in vivo sensitivity of normal and malignant pre-B lymphocytes to ABT-737. They also highlight fundamental differences in expression of Bcl-2 family proteins between autonomously dividing cell lines and ALL xenografts This article has not been copyedited and formatted. The final version may differ from this version. established from direct explants, which may partly explain the divergence in their sensitivity to ABT-737.
Synergistic interactions between ABT-737 and chemotherapeutic drugs against pediatric ALL.
ABT-737 augments the activity of established drugs against cancer cell lines Tahir et al., 2007) , including the in vivo efficacy of a 3-drug regimen (VCR, DEX, and L-asp) against pediatric ALL xenografts (Kang et al., 2007) . We reasoned that it would be possible to use this xenograft model to rationally design effective combination regimens between ABT-737 and drugs known to be active in the treatment of pediatric ALL, which could be rapidly translated to the clinic. To develop this paradigm we selected an aggressive xenograft derived from a child at early relapse (ALL-19), which was previously shown to exhibit relative resistance to VCR and DEX in vivo (Liem et al., 2004) . Using fixed-ratio combination ex vivo cytotoxicity assays ABT-737 exerted strong synergy (average CI The most stringent definition of therapeutic synergy is "a therapeutic effect achieved with a tolerated regimen of a combination treatment that exceeds the optimal effect achieved at any Table 4 ). In the case of the TPT/ABT-737 combination the effects were significantly greater than ABT-737 alone at its MTD (***P=0.0001), while the L-asp/ABT-737 combination was equivalent to single-agent ABT-737 at its MTD ( Figure 5A and Supplementary Table 4 ). These findings provide additional evidence for the rational combination of a Bcl-2 inhibitor with L-asp or TPT in the treatment of pediatric ALL.
To test the generality of our findings, fixed-ratio combination cytotoxicity assays were carried out on an additional 5 xenografts, and all showed synergy or strong synergy between ABT-
and L-asp or TPT (Supplementary Figures 2 and 3 and Supplementary Table 5).
Rationale for combining ABT-737, TPT and L-asp in the treatment of ALL. Since we have shown above that ABT-737 exerts synergistic ex vivo and in vivo anti-leukemic effects when combined with either TPT or L-asp, we further explored the rationale to develop this 3-drug combination.
First, we examined the effects of these drugs on the levels of key apoptosis regulatory proteins in ex vivo cultured xenograft cells. Consistent with its properties as a DNA damaging agent, a concentration of TPT that is achievable in the plasma of cancer patients (Zamboni et al., 1998) , 17
On this assumption we tested the triple drug combination against ALL-19. The combination of TPT, L-asp and ABT-737 was strongly synergistic ex vivo (average CI=0.19; Figure 5D , left, Supplementary Table 2) . Importantly, the 3-drug combination delayed the in vivo progression of ALL-19 by >50 days more than expected if the effects of the three drugs were merely additive ( Figure 5C , Supplementary Table 6 ). In this experiment, ABT-737 and L-asp alone were ineffective in delaying the progression of ALL-19, TPT caused a significant delay (34.9 days; ***P=0.0002 versus controls), while the triple combination resulted in a delay of 85.5 days. In the triple combination group only 3 out of 7 mice reached a leukemia-related event; deaths of the remaining mice were presumed to be age related. Importantly, the in vivo synergistic effect of the triple combination was much greater than either the double combination of ABT-737/L-asp or ABT-737/TPT.
To verify the generality of the in vivo synergy between TPT, L-asp and ABT-737 an additional 2 chemo-resistant xenografts were tested. In each case the 3-drug combination resulted in
LGDs that were greater than the sum of the LGDs for each single agent (Supplementary Figure 5 and Supplementary Table 7) .
To further understand the mechanism by which TPT and ABT-737 cause synergistic cytotoxicity against ALL cells we used the MDM2 antagonist, Nutlin-3, to activate the p53 pathway in the absence of DNA damage. The synergistic effects of ABT-737/Nutlin-3 were almost identical to those of ABT-737/TPT ( Figure 5D , right); supporting the notion that p53 activation, rather than DNA damage per se, is the underlying mechanism.
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Discussion
The principal findings of this study are that: (1) Bim protein expression levels appear to be an important determinant of in vivo and ex vivo sensitivity of normal and malignant immature B lymphocytes to ABT-737; and (2) rationally combining ABT-737 with established chemotherapeutic drugs results in highly synergistic in vivo anti-leukemic effects.
The exquisite ex vivo sensitivity of the pediatric ALL xenografts used in this study appears more closely aligned with that of primary ALL cells than continuously cultured cell lines (Del Gaizo Moore et al., 2008) , supporting the relevance of using direct explants of biopsy material to establish xenografts in immune-deficient mice for pre-clinical drug testing. Moreover, the ex vivo and in vivo sensitivity of the pediatric ALL xenografts to ABT-737 appears to be due to several factors.
First, the panel of xenografts express higher Bcl-2 protein levels than the panel of autonomously growing cell lines used ( Figure 3D ). Recent studies suggest that Bcl-2 dependence, rather than basal Bcl-2 expression levels, have a greater impact on the cellular response to inhibitors such as ABT-737 (Del Gaizo Moore et al., 2008; Deng et al., 2007) . In the xenograft cells, in which most of the Bim protein is sequestered by Bcl-2 ( Figure 3B ), treatment with ABT-737 will cause displacement of Bim, resulting in Bax/Bak activation and apoptosis. This model is consistent with both the direct and indirect pathways of Bax/Bak activation (Letai et al., 2002; Willis et al., 2007) .
Second, our data also suggest that Bcl-2 dependence in the leukemia cell lines is less important in determining cell survival than in the xenograft and primary ALL cells. Therefore, it could be predicted that expression levels of pro-survival proteins not targeted by ABT-737 will be important determinants of sensitivity in cell lines. This is indeed the case, where Mcl-1 expression levels significantly correlated with ABT-737 sensitivity in the leukemia cell lines. Furthermore, the levels of Mcl-1 expression in the entire xenograft panel were comparable to those in the 3 cells lines that were most sensitive to ABT-737 ( Figure 3D correlate with in vivo ABT-737 resistance, the overall low level of expression in the ALL xenografts appears to contribute to their relative sensitivity.
Third, overall expression levels of Bcl-2 family members were less variable across the panel of xenografts compared with the cell lines. This suggests that the intrinsic apoptotic pathway is highly deregulated in the cell lines, and that defects within the pathway are likely to occur at multiple levels. Moreover, leukemia cell lines are more prone to sustain inactivating mutations in Bax and p53, that are not reflective of the primary disease, which also may impact on effective apoptosis-triggering mechanisms (Drexler et al., 2000; Molenaar et al., 1998) . For example, 3 of the cell lines (K562, Nalm-6, Molt-4) appeared to express no Bax protein.
Fourth, we show that Bim (and importantly the amount of Bim associated with Bcl-2)
significantly correlated with the in vivo sensitivity of the panel of xenografts to ABT-737. This correlation is in agreement with the in vitro ABT-737 sensitivity of a panel of human diffuse large B cell lymphomas (Deng et al., 2007) , but in contrast with the in vitro sensitivity of the cell lines used in this study. The importance of Bim expression levels in relation to ABT-737 response was further strengthened by experiments demonstrating that Bim -/-lymphocytes were more resistant to ABT-737 than their wild-type and Puma -/-counterparts. Therefore, the principal mechanism of in vivo ABT-737 resistance in the xenograft panel appears to be reduced expression of a BH3-only protein, Bim, rather than defects in effector proteins (Bax/Bak) or increased expression of antiapoptotic proteins (e.g. Mcl-1) (Deng et al., 2007) . However, while our results suggest an important role for Bim in the sensitivity of ALL xenograft cells to ABT-737, further studies using Bim knockdown are required to demonstrate a direct contribution.
In agreement with a previous study (Del Gaizo Moore et al., 2008) , we have also shown that ABT-737 induces cell death via the mitochondrial pathway in ALL cells. In addition, it has previously been shown using cell lines that pre-treatment with a pan-caspase inhibitor can wholly inhibit ABT-737-induced cell death (Del Gaizo Moore et al., 2008) . In contrast, we show that in xenograft cells pan-caspase inhibition delays, but does not prevent, cell death. This provides This article has not been copyedited and formatted. The final version may differ from this version. evidence that ABT-737 is likely to induce ALL cell death even if caspase activation was blocked.
Our results are consistent with a recent study which demonstrated that, in addition to inducing apoptosis via the intrinsic apoptotic pathway, ABT-737 can induce cell death by promoting outer mitochondrial membrane rupture, a caspase independent process, in primary chronic lymphocytic leukemia cells (Vogler et al., 2009 ).
While this study has shown that, even at a low dose, ABT-737 is relatively effective in vivo as a single agent against a heterogeneous panel of ALL xenografts, the clinical applicability of Bcl-2 inhibitors is most likely to involve combinations with established drugs (Kang et al., 2007; Kuroda et al., 2008; Oltersdorf et al., 2005; Trudel et al., 2007) . In this study we show that ABT- by p53 in response to DNA damage in other model systems (Villunger et al., 2003) . Moreover, both
Noxa and Puma were induced by cyclophosphamide in causing in vivo synergy with ABT-737 against aggressive Myc-driven lymphomas (Mason et al., 2008) . Our results suggest that p53 mediates apoptosis by directly targeting mitochondria in ALL xenograft cells (Mihara et al., 2003) .
The synergistic effects of Nutlin-3 with ABT-737 were almost identical with those of TPT, suggesting that p53 activation per se, rather than DNA damage, was the underlying mechanism of synergy between TPT and ABT-737. However, additional studies using either p53-mutant or knockout cells are required to demonstrate a causal relationship in this regard. Importantly, the synergistic effects between L-asp, TPT and ABT-737 were replicated in 5 additional xenografts, confirming the generality of the interactions.
Based on the above evidence we designed a 3-drug regimen that, by targeting different components of the intrinsic apoptotic pathway, we reasoned should result in a strong synergistic effect (Supplementary Figure 6) . The triple combination was indeed highly synergistic both ex vivo and in vivo, and the in vivo results were confirmed in an additional 2 independent xenograft lines.
The ability of ABT-737 to reverse L-asp resistance in vivo is likely to be of clinical relevance, since poor clinical outcome in pediatric ALL has been associated with L-asp resistance (Fine et al., 2005) .
Moreover, recent evidence suggests that TPT has some clinical activity against relapsed pediatric ALL (Hijiya et al., 2008) . Therefore, the combination of L-asp/TPT and a Bcl-2 inhibitor (e.g. ABT-737 at two doses, 25 and 60 mg/kg; see Table 1 and Supplementary Table 1 for all values. This article has not been copyedited and formatted. The final version may differ from this version. 
